This is the second patent awarded in less than one year for saliva tests to Quadrant Biosciences and its partners, the State University of New York Research Foundation and the  
Penn State Research Foundation

Quadrant’s wastewater testing is now sequencing COVID-19 positive samples to determine the variant lineages, and more than 76% of New York is participating

Suer to expand molecular genetic testing portfolio at Quadrant

Dean will focus on the company’s brand narrative and enhancing its corporate reputation, the company said in a statement. 

To help meet the new federal government testing mandate, Quadrant Biosciences is offering affordable COVID testing to businesses throughout NYS. 

Quadrant Biosciences welcomes Rita Marble to their team as Executive Vice President of Human Resources. Rita brings more than 20 years of leadership experience in the field of Human Resources Management to the Quadrant team.

The use of accurate biomarkers for detecting autism spectrum disorder (ASD) could result in saving billions of dollars in healthcare costs, according to a paper recently published in the journal Autism Research.

Quadrant Biosciences has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the FDA for its innovative Clarifi ASD autism saliva test.

CEO Richard Uhlig recognized for his exemplary leadership during global pandemic.

Quadrant Biosciences announced that Nick Gianadda has joined the company as Chief Technology Officer.

Quadrant Biosciences Inc., announced that Rita Romano has assumed the role of President of it’s newly created Quadrant Laboratories division.

Quadrant Biosciences and SUNY Upstate Medical to receive MedTech’s 2020 Project of the Year award for the development of the Clarifi COVID-19 saliva test.

A simple saliva swab may hold the key to diagnosing and managing mild traumatic brain injury (i.e., concussions), according to a study recently published in the journal Clinical and Translational Medicine.

New test offers simple, easy to administer saliva swab for COVID-19 testing.

Quadrant Biosciences said on Monday that it has received a $2.3 million grant from the National Institutes of Health to develop its saliva-based microRNA diagnostic test for concussions in children and adolescents.

 Dr. Frazier will help guide research and clinical acceptance of the new Clarifi autism saliva test.

Quadrant Biosciences Inc (Quadrant Biosciences) announced today that the American Medical Association (AMA) has issued a new CPT^® Proprietary Laboratory Analyses (PLA) code for its Clarifi ASD™ autism saliva test.

Quadrant Biosciences Inc, a leading developer of epigenetic diagnostic solutions, including the world’s first saliva test for autism, announced that it is now offering common shares of the company (at a price of $3/share, with a minimum investment of $300) through equity crowdfunding platform Wefunder.

Quadrant Biosciences Inc., a developer of novel diagnostic solutions, announced the release of Clarifi ASD™, the first ever epigenetic test for autism spectrum disorder (ASD).

A simple saliva swab may provide an accurate way of detecting Parkinson’s disease in its earliest stages, according to a study just published in the journal Plos One.

Quadrant Biosciences has been awarded a $330,000 grant from the National Institutes of Health (NIH).

Quadrant Biosciences Inc. has been awarded the Technology Business of the Year by the New York State Small Business Development Center (SBDC).

As part of its commitment to helping people with autism and their families and increasing early intervention through early diagnosis, Quadrant Biosciences announced today that they will support Autism Speaks’ mission with funding to expand delivery of reliable information, resources and support through the Autism Speaks Autism Response Team.

Quadrant Biosciences Inc., an emerging life science company based in Syracuse, New York, is pleased to announce its strategic partnership with Admera Health, an advanced molecular diagnostics company headquartered in South Plainfield, NJ.

Quadrant Biosciences Inc., a Syracuse, New York-based Life Science company, announced today that Wall Street veteran Peter Cohen will be joining its Board of Directors.

Motion Intelligence Inc. announced that it has changed its company name to Quadrant Biosciences Inc. The Syracuse, New York-based neuroscience company is involved in the development of functional assessments and epigenetic diagnostic solutions for large-scale health issues.